Labiotech.eu’s Post

Join Our Webinar Tomorrow! "Optimizing Monoclonal Antibody Production: The Impact of Temperature and Osmolality" 📅 Date: Tomorrow, February 8th at 11:00AM (EST)! Secure your spot here: https://lnkd.in/dpSNuyqN... Discover strategies to enhance monoclonal antibody production and understand the influence of temperature and osmolality. Ideal for bioprocess engineers, cell culture scientists, and protein production specialists. Learn about optimizing cell culture conditions and adjusting environmental factors for improved yield and quality. Register now to not miss out on expert insights. #Biopharmaceuticals #MonoclonalAntibodies #BiotechWebinar #BiotechCommunity

Exciting news for the biopharmaceutical industry! Super7, a new interesting passaging concept, can help increase productivity in cell lines and manufacturing processes. According to this article, Super7 is easy to adopt in current and future manufacturing seed trains. I encourage everyone to start testing it in different CHO lineages. Let's think out of the box and explore new ways to improve productivity. Check out the article below and share your thoughts! #highproductivity #CHOK1 #interestingpassagingconcept #fedbatch #thinkoutofthebox https://lnkd.in/gUECWVuD

The advent of new methodologies in perfusion bioreactor optimization is revolutionizing biopharmaceutical manufacturing. Innovations like quasi-perfusion microwell plates (MWP) and mini bioreactors (MBR) significantly enhance efficiency and reduce costs. The blending of glucose-rich supplements with perfusion-specific base media has shown to increase monoclonal antibody titres by eight-fold compared to traditional methods, demonstrating significant improvements in yield and volumetric productivity. This approach, coupled with the high-throughput capabilities of MWPs, enables rapid media optimization, reducing both environmental and financial burdens. Moreover, the integration of AI and machine learning in this field is unlocking new potentials. By focusing on synthetic lethality and loss-of-function mutations, researchers are addressing previously untreatable genetic alterations. This not only expands the therapeutic landscape but also ensures that groundbreaking treatments can be developed and brought to market more efficiently. These advancements exemplify the transformative impact of combining cutting-edge technology with innovative bioprocessing methodologies, paving the way for more effective and accessible cancer treatments. #Biopharmaceuticals #PerfusionBioreactors #AIinHealthcare #SyntheticLethality #PrecisionMedicine #CancerTreatment #Biotechnology #HighThroughputScreening https://lnkd.in/gJduRKf3

With so many recombinant proteins expressed in CHO cells which have been preadapted to desirable growth conditions these days, it can be easy to forget the challenges with adapting cell lines into suspension culture! Here's an interesting paper where the authors have taken a cell line engineering approach to make suspension adaptation faster and more efficient (and improve transfection efficiency) - by identifying factors that were associated with anchorage-independent growth, and then using inducible expression of these factors for suspension adaptation. #biotherapeutics #biopharmaceuticals #celllinedevelopment #cellculture #celllineengineering https://lnkd.in/eS3FkZ-s

In the dynamic world of #biopharmaceuticals, the production of monoclonal antibodies (#mAbs) and recombinant proteins using mammalian cells has not just been a trend but a transformative leap forward. Over the last decade, this advancement has propelled a significant influx of #biotherapeutic proteins into the market, revolutionizing patient care and treatment options. As the industry continues to grow, the pressure to reduce development costs and accelerate time-to-market for these life-saving treatments has never been higher. That‘s where our eBook, “Optimize your high-value cell lines,“ comes in! A comprehensive eBook designed to guide you through the complexities of #celllinedevelopment, this essential read offers an in-depth overview of the cell line development workflow, highlighting innovative high-throughput solutions that streamline the process, making it easier and faster to identify and select high-producing mammalian cell lines. Download now and pave the way for faster, more efficient delivery of next-generation biotherapeutics. 👇 https://lnkd.in/gZUCnQ2h Clone Screening | Molecular Devices

If your Biologics entail complexities such as ADC (Antibody Drug Conjugate) and it is a non-glycosylated Fusion Protein or Domain Antibody, leverage the Development & Scale-up proficiency offered by the Paras Biopharmaceuticals Finland team. Paras Biopharmaceuticals Finland specializes in custom solutions for complete biologics development and manufacturing. Based in Finland with state-of-the-art facilities our expert team of scientists are proficient in handling every stage of the biologics manufacturing process, from gene manipulation to scale-up production, with the ability to deliver batches within a span of just 10 months. From concept to commercialization, we're dedicated to delivering excellence every step of the way. We collaborate & partner with you, using our… ✅ Cutting-edge technology ✅ Unparalleled expertise ✅ Tailored solutions for your unique needs ✅ Commitment to quality and compliance Unlock with us the full potential of your biologics projects. Together, let's shape a healthier, more sustainable future! #Biologics #Innovation #Biosimilars #CDMO #Biopharma #production #manufacturing

If your Biologics entail complexities such as ADC (Antibody Drug Conjugate) and it is a non-glycosylated Fusion Protein or Domain Antibody, leverage the Development & Scale-up proficiency offered by the Paras Biopharmaceuticals Finland team. Paras Biopharmaceuticals Finland specializes in custom solutions for complete biologics development and manufacturing. Based in Finland with state-of-the-art facilities our expert team of scientists are proficient in handling every stage of the biologics manufacturing process, from gene manipulation to scale-up production, with the ability to deliver batches within a span of just 10 months. From concept to commercialization, we're dedicated to delivering excellence every step of the way. We collaborate & partner with you, using our… ✅ Cutting-edge technology ✅ Unparalleled expertise ✅ Tailored solutions for your unique needs ✅ Commitment to quality and compliance Unlock with us the full potential of your biologics projects. Together, let's shape a healthier, more sustainable future! #Biologics #Innovation #Biosimilars #CDMO #Biopharma #production #manufacturing

If your Biologics entail complexities such as ADC (Antibody Drug Conjugate) and it is a non-glycosylated Fusion Protein or Domain Antibody, leverage the Development & Scale-up proficiency offered by the Paras Biopharmaceuticals Finland team. Paras Biopharmaceuticals Finland specializes in custom solutions for complete biologics development and manufacturing. Based in Finland with state-of-the-art facilities our expert team of scientists are proficient in handling every stage of the biologics manufacturing process, from gene manipulation to scale-up production, with the ability to deliver batches within a span of just 10 months. From concept to commercialization, we're dedicated to delivering excellence every step of the way. We collaborate & partner with you, using our… ✅ Cutting-edge technology ✅ Unparalleled expertise ✅ Tailored solutions for your unique needs ✅ Commitment to quality and compliance Unlock with us the full potential of your biologics projects. Together, let's shape a healthier, more sustainable future! #Biologics #Innovation #Biosimilars #CDMO #Biopharma #production #manufacturing

Microbial Identification: Advancing Therapeutic Development As we advance deeper into the biotech and pharma landscapes, the critical role of microbial identification continues to gain momentum. The recent report on the Microbial Identification Market projects an impressive growth trajectory, reaching $8.1 billion by 2033. This expansion highlights the increasing reliance on precision tools to identify and understand microbial populations that impact therapeutic pipelines. For companies with a stake in biologics, cell and gene therapies, or microbiome-based therapeutics, this evolving market offers not just opportunities but a necessity to integrate advanced microbial identification technologies into R&D and production workflows. These tools are essential for: Ensuring product purity and safety throughout development.  Optimizing manufacturing processes by identifying contaminants and enhancing strain productivity.  Supporting regulatory compliance in line with FDA and EMA standards for microbial control. As biotech continues to embrace complex biologics, from monoclonal antibodies to gene-editing platforms, the demand for robust microbial identification systems will only intensify. Pharma leaders must stay ahead by leveraging these technologies to minimize risk, ensure efficacy, and drive faster, more accurate therapeutic development. For more information visit this link: https://lnkd.in/dD9R7ubT BioSpace #Biotechnology #Pharmaceuticals #TherapeuticDevelopment #Biologics #Microbiome

If your Biologics entail complexities such as ADC (Antibody Drug Conjugate) and it is a non-glycosylated Fusion Protein or Domain Antibody, leverage the Development & Scale-up proficiency offered by the Paras Biopharmaceuticals Finland team. Paras Biopharmaceuticals Finland specializes in custom solutions for complete biologics development and manufacturing. Based in Finland with state-of-the-art facilities our expert team of scientists are proficient in handling every stage of the biologics manufacturing process, from gene manipulation to scale-up production, with the ability to deliver batches within a span of just 10 months. From concept to commercialization, we're dedicated to delivering excellence every step of the way. We collaborate & partner with you, using our… ✅ Cutting-edge technology ✅ Unparalleled expertise ✅ Tailored solutions for your unique needs ✅ Commitment to quality and compliance Unlock with us the full potential of your biologics projects. Together, let's shape a healthier, more sustainable future! #Biologics #Innovation #Biosimilars #CDMO #Biopharma #production #manufacturing